Mannkind Corporation Receivables Turnover Ratio (MNKD), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Mannkind Corporation  (NASDAQ: MNKD)
 

Mannkind Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Mannkind Corporation's ability to collect accounts receivable sequentially worsen to 12.39, indicating more challenging environment then in the first quarter 2026, but still, it is a far cry from any concerns. Mannkind's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 29 days, from 28 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 90 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 686 to 899.

What is Receivable Turnover Ratio?
What is Mannkind Corporation Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MNKD Receivables Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Receivable Change 59.19 % -2.64 % 225.03 % -4.4 % 16.26 %
Y / Y Revenue Change 42.92 % 15.08 % 45.82 % 17.2 % 5.72 %
Receivable Turnover Ratio (TTM) 12.39 13 12.49 14.73 14.03
MNKD's Total Ranking # 899 # 686 # 787 # 1366 # 1271
Accounts Receivable average collection period days 29 28 29 25 26
Seq. Receivable Change 53.56 % -26.66 % 120.72 % -35.96 % -6.08 %
Seq. Revenue Change 21.3 % -19.46 % 36.31 % 7.32 % -2.33 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 38
Healthcare Sector # 91
Overall Market # 899

Receivable Turnover Ratio Statistics
High Average Low
20.31 11.82 2.3
(Jun 30 2017)   (Sep 30 2017)




  News about Mannkind Corporation Receivables Turnover Ratios

MannKind Corporation Advances in Pulmonary Fibrotic Disease Treatment and Shows Stronger Financial Health

MannKind Corporation Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases MannKind Corporation has announced a significant milestone with the successful completion of a Phase 1 clinical trial for its innovative dry powder inhaler (DPI) formulation of nintedanib, targeted at treating pulmonary fibrotic diseases. This breakthrough in the company s product pipeline holds promise for patients suffering from conditions such as idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases, where current treatment options are limited.The Phase 1 trial was designed to assess the safety, tolerability, and pharmacokinetics of nintedanib DPI, and the results have shown positive outcomes, reinforcing MannKind s commitment to addressing unmet medical needs in the respiratory space. Nintedanib, a well-characterized tyrosine kinase inhibitor, has previously been approved in oral formulation for treating IPF, but this novel delivery method aims to enhance patient adherence and improve bioavailability.


MNKD Company Profile • Back to MNKD Efficiency Comparisons • Compare MNKD Receivables Turnover Ratio to its Competitors

Financial Statements
Mannkind's Accounts Receivable $ 43 Millions Visit MNKD's Balance sheet
Mannkind's Sales TTM $ 394 Millions Visit MNKD's Income Statement
Sources of MNKD's Revenues Visit MNKD's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
MNKD's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
MNKD's Growth Rates MNKD's Roa MNKD's Inventory Turnover Ratio MNKD's Dividend Comparisons
MNKD's Profitability Ratios MNKD's Roi MNKD's Asset Turnover Ratio MNKD's Dividend Growth
MNKD's Valuation Ratios MNKD's Roe MNKD's Financial Strength Ratios MNKD's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026
Sonida Senior Living Inc   23.90 $ 525.973  Millions$ 22.008  Millions
Marpai Inc  23.52 $ 16.635  Millions$ 0.707  Millions
Agenus Inc  22.44 $ 132.693  Millions$ 5.914  Millions
U S Physical Therapy Inc  22.40 $ 812.203  Millions$ 36.251  Millions
Nutriband Inc   22.15 $ 1.618  Millions$ 0.073  Millions
Lineage Cell Therapeutics Inc   20.02 $ 13.083  Millions$ 0.654  Millions
Hims and Hers Health Inc   19.65 $ 2,578.494  Millions$ 131.228  Millions
Neuraxis Inc   18.95 $ 5.316  Millions$ 0.281  Millions
China Pharma Holdings Inc  18.55 $ 3.914  Millions$ 0.211  Millions
Bausch Health Companies Inc   18.42 $ 10,853.000  Millions$ 589.250  Millions
Arvinas Inc   17.26 $ 316.700  Millions$ 18.350  Millions
Nrx Pharmaceuticals Inc   17.25 $ 3.394  Millions$ 0.197  Millions
Polomar Health Services, Inc.  17.19 $ 3.172  Millions$ 0.185  Millions
Anika Therapeutics Inc   16.70 $ 121.370  Millions$ 7.266  Millions
Lifemd Inc   16.48 $ 163.363  Millions$ 9.915  Millions
Longeveron Inc   16.43 $ 1.187  Millions$ 0.072  Millions
Bioage Labs Inc   15.82 $ 10.355  Millions$ 0.655  Millions
Vaxart Inc   15.09 $ 243.064  Millions$ 16.108  Millions
Medicinova Inc   15.02 $ 0.920  Millions$ 0.061  Millions
Voyager Therapeutics Inc   14.71 $ 34.459  Millions$ 2.343  Millions
Halozyme Therapeutics Inc   14.68 $ 1,663.738  Millions$ 113.332  Millions
Nexgel Inc   14.52 $ 11.810  Millions$ 0.813  Millions
Skinhealth Systems Inc   14.42 $ 289.224  Millions$ 20.051  Millions
Lftd Partners Inc   14.13 $ 35.335  Millions$ 2.500  Millions
Talkspace Inc   14.09 $ 246.631  Millions$ 17.506  Millions
Lifestance Health Group Inc   14.07 $ 1,584.834  Millions$ 112.665  Millions
10x Genomics Inc   13.90 $ 616.566  Millions$ 44.342  Millions
Amneal Pharmaceuticals Inc   13.90 $ 3,117.474  Millions$ 224.342  Millions
Ataibeckley Inc   13.83 $ 4.473  Millions$ 0.324  Millions
Corcept Therapeutics Inc  13.54 $ 830.813  Millions$ 61.352  Millions

Date modified: 2026-09-11T09:42:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.